ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 1:20 p.m. ET in Coral Gables, FL.
馬薩諸塞州劍橋和安大略省多倫多，2024年11月26日（GLOBE NEWSWIRE）——一家處於臨床階段的生物技術公司ProMis Neurosciences Inc.（納斯達克股票代碼：PMN）今天宣佈，針對阿爾茨海默氏病（AD）、肌萎縮性側索硬化（ALS）和多系統萎縮（MSA）等神經退行性疾病中毒性錯誤摺疊蛋白的抗體療法 Promis Neurosciences首席執行官Warma將在第七屆Evercore HealthConx年度會議上參加爐邊談話美國東部時間 2024 年 12 月 3 日星期二下午 1:20 在佛羅里達州科勒爾蓋布爾斯。
A live webcast of the fireside chat may be accessed by visiting the Events page of the Company's website at , and will be available for at least 30 days following the event.
可以通過訪問公司網站的 「活動」 頁面來觀看爐邊聊天的網絡直播，網址爲 ，並且將在活動結束後至少 30 天內可用。
About ProMIS Neurosciences Inc.
關於 PromiS Neuroscienc
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.
ProMis Neurosciences Inc. 是一家臨床階段的生物技術公司，專注於研發選擇性地針對阿爾茨海默氏病（AD）、肌萎縮性側索硬化（ALS）和多系統萎縮（MSA）等神經退行性疾病中毒性錯誤摺疊蛋白質的抗體療法。該公司專有的靶標發現引擎應用熱力學計算發現平台——ProMIS和集體座標——來預測錯誤摺疊蛋白分子表面上被稱爲疾病特異表位的新靶標。PMN310 是該公司治療AD的主要候選產品，是一種差異化的人源化單克隆抗體，旨在特異性結合有毒的Aβ低聚物，不結合斑塊或單體。衆所周知，低聚物會推動 AD 的疾病進展，而 PMN310 似乎是唯一選擇性結合低聚物的抗體，有望支持更好的安全性和有效性。PMN 310已成功完成1a期臨床研究，ProMis預計將在2024年底之前啓動針對AD患者的10期臨床試驗。ProMis在馬薩諸塞州劍橋和安大略省多倫多設有辦事處。
For further information:
欲了解更多信息：
Visit us at .
請訪問我們 .
Please submit media inquiries to info@promisneurosciences.com.
請將媒體詢問提交至 info@promisneurosciences.com.
For Investor Relations, please contact:
有關投資者關係，請聯繫：
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
Precision AQ（前身爲斯特恩投資者關係）
安妮·瑪麗·菲爾茲，董事總經理
annemarie.fields@precisionaq.com
電話 212-362-1200
